Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human PE-Labeled Human CD19 (20-291) Protein, Fc Tag, 25 tests  

Recombinant Human PE-Labeled Human CD19 (20-291) Protein, Fc Tag, 25 tests

Recombinant Human PE-Labeled CD19 (20-291), expressed in HEK293 cells, AA Pro 20 - Lys 291, Fc Tag

Synonym
CD19, B4, CVID3, MGC12802

More details

CD9-HP254-25tests

Availability: within 7 days

348,00 €

Background
B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

Source
Recombinant PE-Labeled Human CD19 (20-291), Fc Tag is produced via conjugation of PE to Human CD19 (20-291), Fc Tag under optimal conditions. Human CD19 (20-291), Fc Tag is expressed in HEK293 cells containing AA Pro 20 - Lys 291 (Accession # P15391-1).Predicted N-terminus: Pro 20

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.The protein has a calculated MW of 58.9 kDa.

Application
Evaluation of anti-CD19 CAR expression by flow cytometry (Please note that this product is NOT compatible to streptavidin detection system).

Conjugate
PE
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 575 nm

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Bioactivity
FACS Analysis of Anti-CD19 CAR Expression
1e6 of the CD19-CAR-293 cells were stained with 100ul of 1:50 dilution (2ul stock solution in 100ul dilution buffer) of PE-Labeled Human CD19 (20-291), Fc Tag (Cat. No. CD9-HP254). PE Streptavidin was used as negative control (QC tested).

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

References

(1) Pesando JM, et al., J. Exp. Med. 170 (6): 2159–64.
(2) van Zelm MC, et al., 2006, N. Engl. J. Med. 354 (18): 1901–12.
(3) Bradbury LE, et al., 1992, J. Immunol. 149 (9): 2841–50.
(4) Horváth G, et al., 1998, J. Biol. Chem. 273 (46): 30537–43.
(5) Imai T, et al., 1995, J. Immunol. 155 (3): 1229–39.
(6) Doody GM, et al., 2000, EMBO J. 19 (22): 6173–84.